Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Precision medicine and the FDA's draft guidance on laboratory-developed tests

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: The FDA's proposed risk-based framework for regulatory approval of in vitro diagnostic devices (IVDs).

References

  1. US Food and Drug Administration. Draft Guidance: Framework for Regulatory Oversight of Laboratory Developed Tests (LDT). http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM416685.pdf (FDA, 2014).

  2. Ratner, M. Nat. Biotechnol. 32, 855 (2014).

    Article  CAS  Google Scholar 

  3. Nelson, C. et al. MMWR Morb. Mortal. Wkly. Rep. 63, 333 (2014).

    PubMed  PubMed Central  Google Scholar 

  4. Holtzman, N.A. & Watson, M.S. Final Report of the Task Force on Genetic Testing. http://www.genome.gov/10001733 (US Task Force, 1997).

    Google Scholar 

  5. Buchen, L. Nature 471, 428–432 (2011).

    Article  CAS  Google Scholar 

  6. Saslow, D. et al. Am. J. Clin. Pathol. 137, 516–542 (2012).

    Article  Google Scholar 

  7. Imperiale, T.F. et al. N. Engl. J. Med. 370, 1287–1297 (2014).

    Article  CAS  Google Scholar 

  8. Kwak, E.L. et al. N. Engl. J. Med. 363, 1693–1703 (2010).

    Article  CAS  Google Scholar 

  9. Hwang, T.J., Avorn, J., Carpenter, D. & Kesselheim, A.S. Health Aff. 33, 309–315 (2014).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Aaron S Kesselheim.

Ethics declarations

Competing interests

T.J.H. is employed by Blackstone, but Blackstone and Blackstone's clients were not involved in the decision to pursue this research project and did not contribute in any way to it. The views expressed in this manuscript are those of the authors and do not represent the views of, and do not constitute a recommendation by, Blackstone or any of its affiliated or subsidiary entities. The authors' employers, grantors and funders had no role in the design and conduct of the study; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hwang, T., Lehmann, L. & Kesselheim, A. Precision medicine and the FDA's draft guidance on laboratory-developed tests. Nat Biotechnol 33, 449–451 (2015). https://doi.org/10.1038/nbt.3221

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3221

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research